期刊文献+

Cox-2在乳腺癌多药耐药中的作用及其与P-gp、MRP1的关系

Role of cyclooxygenase-2 in multidrug resistance of breast cancer and relationship with P-gp and MRP1
下载PDF
导出
摘要 目的通过检测环氧合酶-2(cyclooxygenase-2,Cox-2)抑制剂尼美舒利(nimesulide)对人乳腺癌细胞株MDA-MB-231的对化疗药物敏感性及其对P-gp、MRP1表达的影响,探讨Cox-2在乳腺癌细胞肿瘤多药耐药(multidrug resistance,MDR)中的作用及其作用机制。方法 (1)MTT法检测丝裂霉素(MMC)及其与不同浓度Cox-2抑制剂nimesulide联合作用对MDA-MB-231的抑制作用(IC50);(2)流式细胞术检测不同浓度nimesulide作用后,细胞凋亡率的变化及Cox-2、P-gp、MRP1的表达情况。结果 (1)以25、50μmol/L的nimesulide与MMC联合作用,MDA-MB-231细胞的IC50值(5.89±0.66、3.31±0.30)小于MMC单独作用的IC50值(8.59±1.16)且呈剂量依赖性,差异有统计学意义;(2)nimesulide可诱导细胞凋亡,且随着浓度的增加,凋亡率也随之增加(0.13±0.15至29.2±0.95),差异有统计学意义;(3)25、50μmol/L nimesulide作用于MDA-MB-231细胞后,Cox-2、P-gp、MRP1的表达值均下降。结论 nimesulide能增加乳腺癌细胞株MDA-MB-231对化疗的敏感性,诱导细胞凋亡;Cox-2参与肿瘤多药耐药(MDR),且可能通过影响P-gp、MRP1的表达来实现。 Objective To investigate the role of Cox-2 in the multidrug resistance of breast cancer by studying the effect of Cox-2 inhibitor nimesulide on chemotherapy sensitivity of breast cancer MDA-MB-231 cells and its effect on the expression of P-glycoprotein and MRP1.Methods(1)MTT assay was used to compare the inhibiting rate IC50 in breast cancer MDA-MB 231 cell line treated with mitomycin alone or with mitomycin in combination with different doses of nimesuli.(2)The effection of nimesulide on apoptosis and the expression of Cox-2,P-gp was investigated by flow cytometry.Results(1)Compared with MDA-MB-231 cells explored to MMC alone(8.59±1.16),the IC50 of MDA-MB 231 cells decreased after combined with 25 and 50 μmol/L of nimesulide(5.89±0.66,3.31±0.30),and in a dose dependent manner in vitro.(2)It was showed that nimesulied could stimulate apoptosis of MDA-MB 231 cells and in a dose dependent manner(from 0.13±0.15 to 29.2±0.95).(3)Explored to 25 and 50 μmol/L of nimesulide,the expressions of Cox-2,P-gp and MRP1 decreased.Conclusions Nimesulide could enhance chemotherapy sensitivity of mitomycin and stimulate apoptosis in breast cancer MDA-MB-231 cell line.Cox-2 takes part in multidrug resistance of breast cancer,and perhaps it realizes the effect by regulating the expression of P-gp and MRP1.
出处 《实用肿瘤杂志》 CAS 北大核心 2010年第5期542-545,共4页 Journal of Practical Oncology
关键词 乳腺肿瘤/病理学 前列腺素内过氧化物合酶 基因 MDR 尼美舒利/治疗应用 糖蛋白类 细胞凋亡 breast neoplasms/pathology cyclooxygenase-2 gene MDR nimesulide/therapeutic use glycoproteins apoptosis
  • 相关文献

参考文献6

  • 1Patel VA, Dunn M J, Sorokin A, et al. Regulation of MDR-1 ( P-glycoprotein ) by Cyclooxygenase-2 [ J ]. J Biol Chem,2002,277 (41) :38915 - 38920.
  • 2Zatelli MC, Luchin A, Piccin D, et al. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism[ J]. J Clin Endocrinol Metab, 2005,90( 10), 5754 - 5760.
  • 3Yamada T,Takaoka AS, Naishiro Y, et al. Transactivation of the muhidrug resistance gene by T-cell factor 4/beta- catenin complex in early colorectal carcinogenesis [ J ]. Cancer Res,2000 ;60 ( 17 ) : 4761 - 4766.
  • 4van Wijnqaarden J, van Beek E, van Rossum G, et al. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB-231 cells by NF-xappaB mediated increase of intracellular doxorubicin accumulation[ J]. Eur J Cancer, 2007,43 ( 2 ) :433 - 442.
  • 5McCarty MF, Block KI. Preadministration of high-dose salicylates, suppressors of NF-xappaB activation, may increase the chemosensitivity of many cancers : an example of proapoptotic signal modulation therapy [ J ]. Integr Cancer Ther ,2006,5 ( 3 ) :252 - 268.
  • 6Kang HK, Lee E, Pyo H, et al. Cyclooxygenase- independent down-regulation of muhidrug resistance- associated protein-1 expression by celecoxib in human lung cancer cells[ J]. Mol Cancer Ther,2005,4(9) :1358 - 1363.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部